Is lenvatinib/lenvatinib (Lenvima) a targeted anti-cancer drug?

Lenvatinib/Lenvatinib is a targeted anti-cancer drug that is widely used in the treatment of various malignant tumors. Developed by the Japanese company Eisai, this drug is a multi-target tyrosine kinase inhibitor (multi-kinase inhibitor). Its main mechanism of action is to inhibit tumor angiogenesis and cancer cell growth signaling pathways, thereby blocking the tumor's nutrient supply and metastasis ability. Different from traditional chemotherapy, lenvatinib can intervene in the tumor microenvironment and reduce the incidence of side effects by selectively targeting multiple receptors such as VEGFR1-3, FGFR1-4, PDGFRα, RET and KIT. Therefore, it is classified as a typical targeted anti-cancer drug.

Lenvatinib's global clinical studies have shown its potential efficacy in various tumors such as kidney cancer, liver cancer, thyroid cancer, and endometrial cancer. Especially in the field of advanced liver cancer, lenvatinib has become an important first-line treatment drug after sorafenib. It can prolong the progression-free survival of patients, while achieving tumor shrinkage and even stabilizing the disease in some patients. Foreign experts pointed out that lenvatinib's multi-target mechanism enables it to show higher and sustained efficacy in the treatment of drug-resistant tumors.

In China, lenvatinib has been approved for marketing by the National Food and Drug Administration (NMPA) and has been included in the national medical insurance directory, significantly reducing the financial burden on patients. After medical insurance negotiations, the price of lenvatinib has dropped significantly compared with the original price, making the drug affordable to more patients with advanced cancer. At the same time, the combination treatment of lenvatinib and immune checkpoint inhibitors (such as pembrolizumab) has become a new research direction, showing the potential of synergistic anti-tumor.

Overall, lenvatinib not only fully meets the definition of a targeted anti-cancer drug in terms of mechanism, but also represents an important achievement in medical development in terms of clinical application. With multi-target inhibition as its core, it has become a new treatment hope for patients with advanced cancer by interfering with tumor angiogenesis and signaling pathways.

Reference materials:https://www.lenvima.com/